A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now.

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their medications elsewhere.

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they will be prohibiting like-for-like compounded versions.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded GLP-1s—medications containing the same active ingredients as the blockbuster weight-loss drugs but sold at a much lower price.

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of Novo Nordisk's weight-loss drug Wegovy until a federal court delivers its ruling in a lawsuit against the agency.

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.